Microba Life Sciences (MAP) Q3 2025 earnings summary

Executive summary

• Achieved strong growth in core diagnostic test sales, with MetaXplore and MetaPanel adoption accelerating in Australia and the UK, and record months for both products; strategic focus on core diagnostics and supplements, with legacy products replaced and research services divested.

• Announced landmark clinical study results for MetaPanel in inflammatory bowel disease, leading to major partnerships with leading gastroenterology clinics and integration into clinical protocols.

• Transitioned therapeutics business to a capital-light, partnering-focused, and revenue-driven model, targeting non-dilutive funding for live biotherapeutics and next-generation probiotics.

Financial highlights

• FY25 full-year revenue guidance of $15.25m–$16.25m, representing 26%–34% year-on-year growth.

• Q3 FY25 unaudited revenue was $3.43m, down 14% vs PCP, reflecting transition away from research services; core Personal Testing and Supplements revenue grew 3.5% to $3.3m.

• Cash and equivalents at 31 March 2025 totaled $12.41m.

• Q3 FY25 cash receipts were $4.23m, up 9.3% vs PCP and 5.2% sequentially.

Outlook and guidance

• Forecasts strong Q4 and continued robust growth for the full year, with full market access for MetaXplore in the UK expected by end of June 2025.

• US market entry strategy progressing, starting with a cash-pay model and initial hires planned before end of 2025.